We conclude that the chromogranin A promoter contains both positive and negative domains governing its cell type-specific pattern of transcription, and that a small proximate region of the promoter, containing novel as well as previously described elements, interacts specifically with neuroendocrine nuclear proteins, and is thereby sufficient to ensure widespread neuroendocrine ex-
Introduction
Amine-and peptide-producing neuroendocrine cells possess a highly specialized secretory phenotype; some features of this phenotype, such as dense core granules of the regulated secretory pathway (1, 2) , are universal characteristics of such cells.
The chromogranin/secretogranin protein family has a ubiquitous distribution in secretory granules throughout the neuroendocrine system (3) (4) (5) . Members of this protein group share ancestral exons, and may thus constitute an ancient gene family (6, 7) . These acidic, soluble proteins are co-stored and coreleased, by exocytosis, with virtually all amine and peptide hormones and neurotransmitters (3) (4) (5) . Within hormone storage granules, these proteins may osmotically stabilize granule cores by complexing other secretory components (8) , and may modulate prohormone processing (9) ; before and upon release, chromogranins/secretogranins are proteolytically cleaved to a series of active peptides which may act in the extracellular space to control further hormone release from the secretory cell (10) (11) (12) (13) (14) .
Among the chromogranins/secretogranins, perhaps the most widespread in distribution, especially in neuroendocrine neoplasia (15) , is chromogranin A, a 48-kD protein encoded by a recently isolated (6, 7) eight-exon gene whose chromosomal position has been established in homologous (conserved) regions in man (16, 17) , mouse (18) , rat (18) , and cattle (19) .
Because the chromogranin A gene has such a widespread neuroendocrine pattern of expression (3-5, 11, 15) , yet its expression is confined to the neuroendocrine system, excluding expression in purely exocrine tissues or nonpeptide-producing endocrine tissues (3-5, 11, 15) , it occurred to us that its transcriptional control region might provide unique insights into acquisition of the neuroendocrine secretory phenotype.
We therefore isolated a functional transcriptional control region from the chromogranin A gene, characterized its expression in neuroendocrine (versus control) cells, defined functional domains within this promoter, and analyzed interactions between the promoter and neuroendocrine nuclear proteins. Our results suggest that the chromogranin A 5' flanking region contains multiple positive and negative functional transcriptional control regions, most of which behave as promoter rather than enhancer domains. In the minimal neuroendocrine cell typespecific control region, neuroendocrine nuclear proteins recognized well-known as well as novel DNA sequences.
These results suggest the potential for novel cis-and transacting elements giving rise to the neuroendocrine secretory phenotype.
Methods
Mouse and rat chromogranin A genomic clone isolation and characterization. Genomic clones were isolated from mouse (strain AJ) and rat genomic DNA libraries in the BamHI site of the cosmid vector sCos-1 (20, 21) , as previously described (6) . Clones were restriction mapped as previously described (6) .
Promoter terminology. Promoter fragments are oriented and numbered with reference to the transcription initiation (cap) site as +1. For example, a fragment from -1 135 to +52 spans a region from 135 bp upstream (5') of the cap site to 52 bp downstream (3') of the cap site.
Cap site and sequencing. The transcription initiation (cap) site was established both by primer extension, as previously described (6) , and by RNAse protection analysis (22) . An EcoRI-PstI genomic fragment, spanning positions -1135 to +52 bp, was subcloned into pBluescript (Stratagene, La Jolla, CA), and linearized with Kpnl at position -181 bp. This template was used to synthesize antisense RNA, priming at the T3 phage promoter and using T3 RNA polymerase. The source of sense neuroendocrine mRNA was the mouse pituitary corticotrope cell line AtT-20/Dl6v (23) , while sense control (non-endocrine) mRNAs came from mouse liver and a murine erythroleukemia cell line MEL.
The same EcoRI-PstI fragment (-1135 to +52 bp), was sequenced on both strands by the dideoxy chain termination method (24) .
Sequence homology searches. The neuroendocrine cell type-specific region of the chromogranin A promoter sequence (-260/-40 bp) was aligned to known transcription factor recognition sites ("Transcription factors" database), as well as to all sequences recorded in GenBank (Entrez version, release 77, 1993; National Center for Biotechnology Information) using the software package Macvector (IBI/Kodak).
Promoter/reporter expression constructs, and promoter deletions. Promoter fragments were subcloned into the polylinker region of the promoterless luciferase reporter vector pXP1 (25) , between the upstream XhoI site and the downstream HindIII site. Correct orientation of all inserts was verified by either asymmetric double restriction digest, or sequencing.
A 4.8-kbp promoter (-4.8 to +42 bp) was subcloned directionally into pXPl, and named pXP-4.8k.
A series of progressive 5' deletions was prepared either by restriction digestion of this plasmid, or by polymerase chain reaction amplification, using oligonucleotide primers containing 5' (upstream) XhoI and 3' (downstream) HindIII adaptors. The regions amplified had various 5' end lengths, and all terminated on the 3' end +42 bp downstream of the cap site. The authenticity of polymerase chain reaction fragments was confirmed both by restriction digestion, and by DNA sequencing (24) across their borders as well as functionally important regions. These constructs were named by their upstream (that is, minus) bp number.
One putative positive promoter/enhancer upstream (distant) domain tested in conjunction with the homologous chromogranin A promoter was a 2.6-kbp fragment (from -4.8 to -2.2 kbp upstream of the cap site), inserted in the usual (correct) orientation just 5' (upstream) of the chromogranin A promoter fragment -426/+42 bp, in the pXP-426 luciferase reporter construct.
Promoter/enhancer domains tested with a heterologous promoter. To test putative positive or negative regulatory domains in the promoter, the following constructs were made, wherein promoter/enhancer fragments were ligated as a single copy into the polylinker immediately upstream (5') of (adjacent to) the heterologous herpes simplex virus thymidine kinase (TK) promoter in the luciferase reporter vector pTK-LUC (S. Hollenberg, V. Giguere, and R. Evans, unpublished data), unless otherwise noted. When specifically noted, some of the promoter fragments were inserted 1.2 kbp distant from the TK promoter, in an AatII site in the prokaryotic portion of the vector (S. Hollenberg, V. Giguere, and R. Evans, unpublished data).
Distant (upstream) region. (29) , the rat anterior pituitary somatolactotrope line GH3 (30) , and the mouse anterior pituitary corticotrope cell line AtT-20 (23) . Control (non-endocrine) cell lines were the mouse fibroblast line NIH-3T3 and the T-antigen-transformed monkey kidney cell line COS (31) .
Cell lines were grown in Dulbecco's modification of Eagle's medium (DME) with penicillin G (100 U/ml) and streptomycin sulfate (100 Mg/ml). The medium for NIH-3T3 and AtT20 cells was supplemented with 10% fetal bovine serum. The medium for COS cells was supplemented with 5% fetal bovine serum. The medium for PC12 cells was supplemented with 5% fetal bovine serum and 10% horse serum.
Transfected plasmid DNAs were grown in E. coli strain HB101. After alkaline lysis, supercoiled plasmids were prepared by banding twice through gradients of CsCl in ethidium bromide (32) .
Cells were transfected by the efficient lipofection method (Lipofectin; GIBCO-BRL, Gaithersburg, MD), at 50-70% cell confluence. I-3 ,ug of total plasmid DNA were used per 6-cm plate. 48 h after transfection, cell extracts wqre prepared for assay of protein (33) , luciferase (27) , and chloramphenicol acetyltransferase (32 
Results
Genomic clone isolation, transcriptional start site, and sequence homologies. Transcriptional initiation (cap) sites for the mouse gene were localized by RNAse protection with RNA from AtT-20 mouse anterior pituitary corticotropes. Three major sites were identified ( Fig. 1 ) of which the most 5 ' (indicated as 57 bp in Fig. 1 ) exactly matched the cap site determined previously by primer extension (6) . Henceforth this start site is referred to as + 1. The quantitatively major start site is at + 11, with a second minor site at +8. No protected fragments were obtained with RNA from mouse liver or mouse erythroleukemia cells, neither of which express the chromogranin A (CgA)I gene.
Mouse and rat genomic clones were sequenced to > 1 kbp upstream of the transcriptional start site (Fig. 2) (56, 57) . By contrast, two non-endocrine cell lines, mouse NIH-3T3 fibroblasts and COS monkey kidney cells, showed only trace levels of luciferase reporter activity.
A series of 5' deletions was constructed to localize the regions of the promoter involved in cell type specificity. Cellspecific expression of the CgA promoter was preserved with promoter deletions down to -77 bp upstream of the cap site, beyond which point neuroendocrine specificity of expression was lost (Table I proximate promoter. The distal region (-4.8 to -2.2 kbp) retained activity when fused to the proximate -426/ +42 bp chromogranin A promoter region (Fig. 4) .
A number of 3 ' deletions of the CgA leader (5 ' untranslated exon 1) region were constructed. When promoters with varying lengths of leader region were fused to luciferase, it became apparent that increasing the length of the leader (up to +158 bp, which marks the translation initiation site [ATG codon] for chromogranin A) augmented luciferase reporter expression (Table H) The indicated promoter domains (from the specified 5' end, to position +42) were ligated to the luciferase reporter in the vector pXPI, and then transfected into the indicated cell type. For each transfection, the plasmid pRSV-CAT, encoding the reporter chloramphenicol acetyltransferase (CAT), was co-transfected, to control for transfection efficiency differences between cell lines and between promoter lengths, and luciferase activity was normalized (ratioed) to CAT activity. Luciferase/CAT ratios were then normalized to the activity of the strong RSV promoter (pRSV-luciferase) in parallel transfections in each cell type, such that the RSV promoter result is 100% for each cell type. SV-40, SV-40 early promoter in the plasmid pSV2ALL\5 (24) . RSV, Rous sarcoma virus long terminal repeat. PC-12, rat adrenal medullary chromaffin cells. GH3, rat anterior pituitary somatolactotropes. AtT-20, mouse anterior pituitary corticotropes. COS, T antigen-transformed monkey kidney cells. NIH-3T3, mouse fibroblasts.
None, the promoterless luciferase reporter vector pXP1. Results are luciferase/CAT ratios, normalized to pRSV-luciferase results (=100%) for each cell type.
The upstream negative promoter region (-988 to -181 bp) in both orientations conferred negative regulation on the heterologous TK promoter, although more effectively in the correct orientation (Table III) . Since 5' deletions suggested that the -258 to -181 bp region was the crucial negative promoter domain, we also tested the ability of this domain to confer negative regulation onto the TK promoter; however, repression was observed only in the correct orientation of this domain (Table III) .
The ability of several more proximate promoter domains (from -159 to -47 bp) to influence the TK promoter was also tested. Neither the domain from -159 to -128 bp nor that from -128 to -99 bp affected TK/luciferase expression, but the domain from -128 to -62 bp augmented luciferase expression, in copy number-dependent fashion. This augmentation was lost when the element was moved 1.2 kbp away (further upstream) from the TK promoter. The domain from -93 to -62 bp also augmented luciferase expression in dose-dependent fashion (4.63-fold with two copies), and the effect was again lost at a distance. The proximate -59 to -47 bp element did not affect luciferase expression (Table III) .
In (Fig. 6 ). All complexes could be competed by a 50-fold molar excess of the unlabeled oligonucleotide.
Sequence homologies in the proximate promoter region. Alignment of the mouse CgA promoter sequence with that of Luciferase reporter activity of chromogranin A promoter/enhancer upstream fragments linked to the heterologous herpes simplex virus thymidine kinase (TK) promoter, and transfected into AtT-20 mouse pituitary corticotropes. Chromogranin A promoter/enhancer fragments were cloned into the enhancerless promoter vector pTK-LUC, either adjacent (5') to the TK promoter, or into an Aatll site in the prokaryotic portion of the vector, 1.2 kbp distant from the TK promoter. Each transfection involved cotransfection with pRSV-CAT, to correct for differences in transfection efficiency of these plasmids of differing size. The results of duplicate transfections are reported as ratios of luciferase activity/ chloramphenicol acetyl transferase (CAT) activity, with normalization by ratio to the activity of the original enhancerless vector into which the fragments were cloned, pTK-LUC (= 1.0). * P < 0.01, t P < 0.05 (versus pTK-LUC alone).
rat and bovine (7) promoters in the proximate promoter region (-236 to +20 bp) revealed several areas of high homology (Fig. 7 A) . Sequence similarity is most striking in the region from -110 to -53 bp. This region contains three of the four binding sites identified by DNaseI footprinting, as well as potential transcription factor binding sites such as SpI (two sites), CREB, GA box, and Xpf-1. A further region of homology was observed between -203 and -186 bp, an area implicated by deletion analysis in negative regulation. The mouse chromogranin A proximate promoter (from -260 to -40 bp) was aligned to sequences in GenBank (Fig.  7 B) . Several regions of sequence similarity were identified in promoter or untranslated regions of other genes expressed in brain or endocrine glands, including the neurotrophin 3 promoter (46/67 residues; GenBank document ID 98999) (58); the homeodomain Bin-i promoter (42/58 residues; GenBank document ID 450151) ( (62) . The sequence similarity extended from -137 to -66 bp, and included many of the potential transcription factor binding sites listed above.
Discussion
Clearcut universal or unifying factors underlying neuroendocrine gene expression have not yet been conclusively elucidated (63, 64) .
Members of the chromogranin/secretogranin protein family are ubiquitous components in the core of secretory granules throughout the neuroendocrine system (3) (4) (5) . Perhaps the most widely expressed such protein, especially in neuroendocrine neoplasia (15) , is chromogranin A. We therefore analyzed its promoter region for clues to mechanisms universally governing gene expression in the neuroendocrine system, that is, elements controlling acquisition of the neuroendocrine secretory phenotype.
The 5' flanking region of the mouse chromogranin A gene supported strong expression of a reporter gene in adrenal medullary chromaffin cells, anterior pituitary corticotropes, and somatolactotropes, but not in two fibroblast lines (Table I, Fig. 3 ).
Deletion analysis identified several functional promoter domains, both positive and negative, that governed chromogranin A expression in neuroendocrine cells. The minimal promoter that retained neuroendocrine specific expression was initially defined by the deletion construct pXP-147. Further deletion to position -77 bp reduced promoter activity by 50% but was still cell specific; deletion of a further 16 bp, down to position -61 bp, reduced promoter activity > 90%, to the level seen in nonendocrine (fibroblast) cells. Thus a neuroendocrine-specific element is disrupted by the deletion to -61 bp. These findings place the 5' limit of this element at (or downstream of) -77 bp; the 3' limit of this element is not yet completely defined, but deletion to -61 bp is sufficient to abolish activity.
Elements between -77 and -147 bp can augment the neuroendocrine-specific expression (Table I, Fig. 3 ), although this region may simply potentiate the effect of the downstream neuroendocrine-specific element (-77/-61 bp). Fragments from this proximate promoter (especially -93/-62 bp) also stimulated a heterologous TK promoter (Table Ill) in copy numberdependent fashion in pituitary corticotropes, but lost effect when moved 1.2 kbp away.
A distal domain (between -4.8 and -2.2 kbp) also stimulated the activity of a minimal chromogranin A promoter (though not a heterologous promoter) in corticotropes.
A negative domain, uncovered between -258 and -181 bp, conferred negative regulation onto the chromogranin A promoter and also repressed a heterologous TK promoter. Of note, this region contained a sequence, CACCTTC (at -197 to -191 bp), which is similar (6/7 bp) to a negative transcriptional regulatory element, CACCTCC, found in the rat collagen II gene (65) . The CACCTTC sequence is found in mouse and rat chromogranin A genes (Fig. 7 A) , while the bovine gene contains the sequence CACCTCC (identical to the collagen element).
Four areas in the minimal proximate positive promoter region were protected from DNaseI digestion by nuclear extracts from AtT-20 neuroendocrine cells (Fig. 5) ; the intervening areas showed hypersensitivity to DNaseI cleavage. All four "footprinted" areas interacted specifically with neuroendocrine nuclear proteins, as well as other non-neuroendocrine cell-specific factors in electrophoretic gel mobility shift assays (Fig.  6) . These results suggest specific interactions between neuroendocrine nuclear proteins and these functionally important proximal promoter regions. The -59/-47 bp gel shift probe (Fig.  6 ) was designed to explore a footprinted promoter region (Fig.  5) ; even though promoter deletion to -61 bp seemed to abolish cell type-specific expression of the promoter (Fig. 3) , neuroendocrine-specific shifted bands from the -59/-47 bp region (Fig. 6 ) may be functionally important, because we have not yet precisely defined the 3' end of the chromogranin A promoter element conferring cell type-specific expression.
Sequence analysis of the minimal promoter highlighted several similarities to consensus binding sites for known transcription factors (Fig. 7 B) . Some of these similarities coincide with the observed footprints, while others do not. Comparison of mouse, rat, and bovine proximal promoter regions (Fig. 7 A) showed conservation of several sites, including an Spi site (51) in the footprint at -122 to -101 bp, an SpI and a CREB site (37) Cyclic AMP stimulates a number of neuroendocrine genes, including chromogranins A (7), B (67), and C (67, 68), dopamine /3-hydroxylase (69), phenylethanolamine-N-methyltransferase (70) , pituitary glycoprotein hormone a subunit (71), prolactin (71) , and renin (72) . In some of these other genes, CREB sites have been implicated in the response to cAMP (73-75). Comparison of the proximate promoter region of chromogranin A with those of chromogranin B (76) and chromogranin C (77), two other secretory vesicle core proteins with similar tissue distribution to chromogranin A (5), shows conservation of the CREB site, despite very low homology in other regions of their proximate promoters. The presence of a CREB site in the neuroendocrine-specific region of the chromogranin A promoter element is thus quite suggestive of functional importance.
Footprinted proximate areas (Fig. 7 A) also included consensus matches for purine-rich GAGA regions (43) and an AP-2 match (35). Purine-rich areas have been implicated in control of insulin gene expression (43) , while AP-2 is widely expressed in neural crest cell lineages (78) .
Areas of extended homology between the proximate chromogranin A promoter region and nontranslated regions of other neuroendocrine-specific genes were identified by GenBank survey. These included an intron sequence in the ryanodine receptor gene (60) , and sequences in the promoters of the neurotrophin-3 (58), Brn-l (59), PDGF-A chain (61) , and IGF-I receptor genes (62) . Most of the sequence similarity occurs in the chromogranin A promoter's G/C-rich areas, which include two Spl sites. In the PDGF-A chain promoter, the similarity occurs in the middle of a G/C-rich element essential for promoter activity (79) , while the similarity in the neurotrophin-3 promoter lies outside the area crucial for glial expression (58) . Whether the similarities constitute functional promoter elements for the Brn-I gene or the IGF-I receptor gene remains to be determined.
A number of other short consensus matches for neuroendocrine transcriptional control elements were noted in the chromogranin A 5' flanking region (see Appendix), including one Brn-2 site (36), a Drosophila homeodomain site (38) , several E box consensus matches (39, 40) , four GHF-1 sites (44), a putative 10-bp neuroendocrine element (48), a neuropeptide Y expression element (49), a Pit-l site (50) , and a Zeste site (55) . However, these recognition sites were generally located well outside of the minimal neuroendocrine-specific functional region (-77/-61 bp) defined by deletion analysis of the chromogranin A promoter (Table I, Fig. 3 , and Appendix).
In conclusion, the chromogranin A 5' flanking region confers neuroendocrine cell type-specific expression in diverse neuroendocrine cell types. A distal positive domain specifically activates the chromogranin A promoter. The proximate promoter contains both positive and negative elements. Cell type specificity is conferred primarily by a region from -61 to -77 bp which contains a conserved CREB site. The minimal proximate promoter contained four ("footprinted") regions pro- ----------------------- teins; these regions were also specifically complexed by such tion factor binding sites, while others were candidates for novel proteins in an electrophoretic gel mobility shift assay. Some of factors governing chromogranin A expression in particular, and these areas corresponded to previously characterized transcripthe neuroendocrine secretory phenotype in general. Pit-i (50) , (growth hormone gene activating) pituitary factor 1; Spl (51), stimulation protein 1; UPE (52), upstream promoter element in glucokinase gene; Xpf (54), exocrine pancreas transcription factor; and Zeste-whit (55), a transcription factor controlling Drosophila development.
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